New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 50ug; ribavirin 200mg;   - combination - 200mg + 50µg - active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin hydrated silica ink lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 80ug; ribavirin 200mg;   - combination - 200mg + 80µg - active: peginterferon alfa-2b 80ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin hydrated silica lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 100ug; ribavirin 200mg;   - combination - 200mg+100µg(clearclick) - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 120ug; ribavirin 200mg;   - combination - 200mg+120µg(clearclick) - active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 150ug; ribavirin 200mg;   - combination - 200mg+150µg(clearclick) - active: peginterferon alfa-2b 150ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 50ug; ribavirin 200mg;   - combination - 200mg+50µg (clearclick) - active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 100ug - powder for injection - 100 mcg - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 120ug - powder for injection - 120 mcg - active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 150ug - powder for injection - 150 mcg - active: peginterferon alfa-2b 150ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 50ug - powder for injection - 50 mcg - active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection